Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£165,627
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.
days to go:
Expired
investment:
£49,990
Currently, the self-employed have fewer admissions to financial services than their employed counterparts do. Hatch aims to give sole traders free-to-use access to real-time credit scores that will allow lenders to make more informed decisions when invoice funding. The company also offers digitising of tax files, one of the most time-consuming admin burdens. Revenue is generated via affiliate fees to those who wish to introduce and facilitate Hatch on their platforms. A beta for 5k users will be launching soon, with half the slots already filled.
days to go:
Expired
investment:
£115,000
Hemspan states that it designs bio-based building systems and products for construction by combining modern methods, technology and hemp to produce net-zero carbon solutions. The company argues that every time an average house is built, the CO2 emitted by the manufacture, transport and assembly of the materials used is around 50 to 60 tonnes. Hemspan says that one hectare of UK-grown industrial hemp can absorb 11 tonnes of CO2 each year with regeneratively farmed hemp capable of sequestering a further 6 tonnes per hectare of CO2 into the soil each year. Hemspan intends to activate significant demand for hemp farming in the UK and develop processing technologies to reduce reliance on imports and enable large scale manufacturing of bio-based cladding and insulation products that spin out of R&D programmes. It asserts that the global industrial hemp market is expected to grow at 25% CAGR reaching US$ 27 billion by 2028. It aims to be a contender in this segment.
days to go:
Expired
investment:
£200,000
Alert Technology Limited is set to transform health and safety best practice for asbestos management by introducing ALERT - a new generation of real-time asbestos monitoring. With the large potential market, Alert will give market priority to the sectors who have demonstrated the greatest need. ALERT is the only solution to the global problem that impacts 30+ industry sectors. Till now, they have successfully launched the ALERT PRO 1000-the first model in the range and won an industry award in the asbestos category. With the investment, they will strengthen their team by recruiting a new Sales Director, Technical Sales Support, Technicians and Service Engineers to boost the in-house team, expand distribution, drive sales, scale-up assembly and service customers.
days to go:
Expired
investment:
£10,000
